Beneficial effects of an anabolic steroid during cytotoxic chemotherapy for metastatic cancer.
To investigate the effects of concurrent administration of an anabolic steroid upon hematopoiesis and metabolism in patients with cancer who were receiving cytotoxic chemotherapy, a randomized trial was conducted. Thirty-three evaluable patients received intensive multiple-agent chemotherapy: 17 received in addition nandrolone decanoate ("Deca-Durabolin"), 200 mg intramuscularly each week. The nandrolone-treated patients showed significantly better maintenance of hemoglobin concentrations and body weight, and a highly significant reduction in number of blood transfusions. Improved survival in the androgen-treated patients did not achieve significance. There were no differences in neutrophil or platelet counts or in tolerance of cytotoxic drugs. Toxicity from nandrolone therapy was minimal.
D045930:Anabolic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004920:Erythropoiesis / Q000187:drug effects; D006801:Humans; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*
D045930:Anabolic Agents; D000970:Antineoplastic Agents; D009277:Nandrolone; D000077603:Nandrolone Decanoate